BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nventa Biopharmaceuticals Corporation (NVN.TO) To Receive $2.8 Million From Escrow Account


8/4/2006 10:40:03 AM

SAN DIEGO, CA, Aug. 4 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation announced today that it will receive Cad$2.8 million from GVIC Publications. These funds were being held in escrow in connection with Nventa's corporate reorganization previously announced on March 16, 2006.

In consideration for the release of the escrowed funds at this time, the Company will pay GVIC Cad$200,000 cash plus Cad$100,000 payable in common shares of the Company and will grant to GVIC a warrant to purchase up to 250,000 common shares of the Company at a price per share equal to $0.44. Receipt of the funds is pending Toronto Stock Exchange approval of the issuance of the associated securities.

About Nventa Biopharmaceuticals Corporation:

--------------------------------------------

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.

CONTACT: Donna Slade, Director, Investor Relations, 6055 Lusk Boulevard, San Diego, CA, USA, 92121, Tel: (858) 202-4900, Fax: (858) 450-6849, dslade@nventacorp.com

Nventa Biopharmaceuticals Corporation

CONTACT: Donna Slade, Director, Investor Relations, 6055 Lusk Boulevard,San Diego, CA, USA, 92121, Tel: (858) 202-4900, Fax: (858) 450-6849,dslade@nventacorp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES